G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
2.
DETECTION OF ANTI-TNF ALPHA DRUG BIOLOGICS AND ANTI-DRUG ANTIBODIES
The disclosure provides fluorescence resonance energy transfer (FRET) assays to detect the presence of anti-TNFα biologics and/or their autoantibodies in a patient sample to monitor TNFα inhibitor therapy and to guide treatment decisions.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
Methods and compositions are disclosed for preparing a predetermined standardized calibration curve, which can be stored on a label, barcode or tag. A lyophilized product containing assay reagents for use in a bioassay and a known amount of analyte. A predetermined calibration curve associated with the lyophilized product. A predetermined calibration curve makes the preparation of a new calibration curve unnecessary. The methods and compositions are useful in bioassays such as a FRET assay, a real-time reverse transcription polymerase (RT-PCR) assay, a chemiluminescence assay, or any other bioassay that elicits a detectable response based on a change in, or appearance of, color, fluorescence, or reflectance.
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
5.
DIFFERENTIAL DETECTION OF VIRAL AND BACTERIAL INFECTIONS
The present disclosure provides assay methods to detect and measure proteins in order to distinguish between a bacterial infection and a viral infection.
Provided herein are methods for accommodating for sample matrix effects in light measurement assays. A selected amount of a light emitting material is added to a sample, and the light output from the sample is measured. By using an algorithm based on the known light emitting material amount and the measured light output, a correction factor for the assay of the sample is determined. The correction factor can be used to adjust subsequent light output measurements of other samples recorded using the assay.
An assay method for detecting the presence or amount of human serum albumin vitamin D, C-reactive protein, or anti-transglutaminase autoantibody (ATA) immunoglobulin A (IgA) and/or ATA IgG in a sample using fluorescence resonance energy transfer (FRET).
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/82 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving vitamins
An assay method for detecting and measuring the presence or amount of glycated hemoglobin in a sample using fluorescence resonance energy transfer (FRET).
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
9.
ASSAY DETECTION METHODS FOR VCAM-1 AND CALPROTECTIN
Methods and compositions are disclosed for preparing a predetermined standardized calibration curve, which can be stored on a label, barcode or tag. A lyophilized product containing assay reagents for use in a bioassay and a known amount of analyte. A predetermined calibration curve associated with the lyophilized product. A predetermined calibration curve makes the preparation of a new calibration curve unnecessary. The methods and compositions are useful in bioassays such as a FRET assay, a real-time reverse transcription polymerase (RT-PCR) assay, a chemiluminescence assay, or any other bioassay that elicits a detectable response based on a change in, or appearance of, color, fluorescence, or reflectance.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
Provided herein are containers for holding a portion of a biological sample such as a fecal sample. The containers include a body that can be sealed with an upper cap that is attached to a sampling pin and a grip member. The sampling pin is configured to collect a predetermined amount of sample in one or more sampling grooves, with excess sample amount optionally removed from the sampling pin by an interior flange of the container body. The grip member is configured to provide the user of the container with improved torque and grip, and to distance the fingers of the user from the sample being collected. Also provided are kits and methods including the disclosed containers.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
13.
DIFFERENTIAL DETECTION OF VIRAL AND BACTERIAL INFECTIONS
The present disclosure provides assay methods to detect and measure proteins in order to distinguish between a bacterial infection and a viral infection.
Provided herein are methods for accommodating for sample matrix effects in light measurement assays. A selected amount of a light emitting material is added to a sample, and the light output from the sample is measured. By using an algorithm based on the known light emitting material amount and the measured light output, a correction factor for the assay of the sample is determined. The correction factor can be used to adjust subsequent light output measurements of other samples recorded using the assay.
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
The disclosure provides fluorescence resonance energy transfer (FRET) assays to detect the presence of anti-TNFα biologics and/or their autoantibodies in a patient sample to monitor TNFα inhibitor therapy and to guide treatment decisions.
An assay method for detecting and measuring the presence or amount of glycated hemoglobin in a sample using fluorescence resonance energy transfer (FRET).
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
17.
ASSAY METHODS FOR THE DETECTION OF HUMAN SERUM ALBUMIN, VITAMIN D, C-REACTIVE PROTEIN, AND ANTI-TRANSGLUTAMINASE AUTOANTIBODY
An assay method for detecting the presence or amount of human serum albumin vitamin D, C-reactive protein, or anti-transglutaminase autoantibody (ATA) immunoglobulin A (IgA) and/or ATA IgG in a sample using fluorescence resonance energy transfer (FRET).
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/82 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving vitamins
18.
ASSAY DETECTION METHODS FOR VCAM-1 AND CALPROTECTIN
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
19.
AN ASSAY METHOD FOR THE DETECTION OF VCAM-1 AND ALPHA-2-MACROGLOBULIN IN BLOOD
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/536 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase
Provided herein are analyzers as well as related methods for measuring both an absorbance and emission of a sample. The analyzer includes light sources for epi-illumination and transillumination of the sample, and detectors for measuring the intensities of excitation, emission, and transillumination light. A dichroic mirror permits a portion of the excitation light to transmit to a detector that monitors changes in excitation light intensity. Temperature sensors allow for signal corrections based on temperature variations of the detectors and sample.
A kit of parts and methods for determining the presence and quantity of one or more therapeutic monoclonal antibody drugs and/or therapeutic monoclonal antibody inhibitor drug antibodies in a biological sample, the method including providing a reaction liquid comprising the sample, a first conjugate with the target of the therapeutic monoclonal antibody and a first conjugated moiety and a second conjugate with the target of the therapeutic monoclonal antibody and a second conjugated moiety, followed by detecting the change in spectrophotometric signal when the complex between the therapeutic monoclonal antibody drug, the first conjugate and a the second conjugate forms.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
The present invention relates to a kit of parts and methods for determining the presence and quantity of one or more TNF-α inhibitor drugs and/or anti-TNF-α inhibitor drug antibodies in one or more biological samples each comprising less than 200 μl, the method comprising the steps of providing a reaction liquid comprising the sample, a first TNF-α conjugate comprising TNF-α and a first conjugated moiety and a second TNF-α conjugate comprising TNF-α and a second conjugated moiety, said second moiety being capable of generating or ameliorating a detectable signal in the presence of a molecular complex comprising a TNF-α inhibitor, followed by detecting the change in signal when the complex between the TNF-α inhibitor drug, the first TNF-α conjugate and a the second TNF-α conjugate forms.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics
patents
